ArticleBMC infectious diseases2025
Opportunistic infections by Brucella anthropi and Brucella intermedia: a case series of rare non-brucellosis diseases in Saudi Arabia.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- First Report and Comprehensive Risk Index ofMicroorganisms · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRecently reclassified under the Brucella genus, Ochrobactrum species are rare opportunistic pathogens in immunocompromised hosts, causing non-brucellosis diseases. They exhibit multi-drug resistance (including AmpC) and often require combination therapy. This is the first study from Saudi Arabia to review infections by Brucella anthropi and Brucella intermedia, focusing on clinical significance, resistance, and outcomes.
methodA retrospective review was conducted on infections caused by B. anthropi and B. intermedia between January 2016 to December 2024. Data on patient demographics, infection type and location, microbial identification, and resistance patterns were collected. Treatment and therapy duration were reviewed, along with outcome assessment. Analysis of the rate of recovery and in-hospital mortality was performed.
resultsOver 8 years, a total of 18 unique cases were identified, after excluding 2 of which were deemed contaminated, totaling 16 cases included, 14 adult and 2 pediatric patients were identified as true infections. Presentations varied between septic shock, respiratory distress, and/or altered mental status. Diagnoses included catheter-related bloodstream infections (n = 9), intra-abdominal infection with or without bacteremia (n = 4), and VAP in the neonate (n = 2), catheter-associated urinary tract infection (CAUTI) (n = 1). B. anthropi was found in eleven (11/16) cases, and B. intermedia in four cases, in addition to one that was not identified to species level. Twelve were monomicrobial (12/16, 75%) and six had polymicrobial growth. Resistance to cephalosporins and piperacillin/tazobactam was observed, but all isolates were susceptible to carbapenems, TMP/SMX, and ciprofloxacin. Three deaths (3/16) were documented, and the remaining thirteen patients survived, and the overall survival rate was 81%.
conclusionB. anthropi and B. intermedia infections are rare overall, mostly identified in blood cultures with variable clinical presentation. Although it can cause severe sepsis and has beta-lactam resistance, the overall outcome if promptly treated is favorable. The distinction from other brucellosis-causing species (B. melitensis and B. Abortus) is essential. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.